Publications by authors named "Kishan Kumar Parida"

Claim this Profile
A
Advancements in tuberculosis diagnostics: An update.
Mainak Ghosh, Monali Lahiri, Aman Dalal, Kishan Kumar Parida, Nitin Pal Kalia

Microb Pathog· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Indole-Linked Triazole Sulfonamide Derivatives as Potent Mycobacterial Carbonic Anhydrase Inhibitors: Leveraging a Tail Approach for the Design, Synthesis, and Studies─An In-Depth Multidisciplinary Study.
Anuradha Singampalli, Rani Bandela, Bulti Bakchi, Sarvan Maddipatla, Pardeep Kumar, Kishan Kumar Parida

J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of β-carboline-benzofuran based hybrids as antibacterial agents against Staphylococcus aureus.
Mursalim Ali Khan, Kishan Kumar Parida, Dastari Sowmya, Naveen Chand Rallabandi, Nitin Pal Kalia

Bioorg Med Chem Lett· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymoquinone loaded nanoemulgel in streptozotocin induced diabetic wound.
Urati Anuradha, Valamla Bhavana, Padakanti Sandeep Chary, Naveen Rajana, Kishan Kumar Parida

Nanomedicine (Lond)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P-glycoprotein inhibitors as an adjunct therapy for TB.
Kishan Kumar Parida, Monali Lahiri, Mainak Ghosh, Aman Dalal, Nitin Pal Kalia

Drug Discov Today· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents.
Rabiya Samoon, Shashikanta Sau, Arnab Roy, Kishan Kumar Parida, Kalicharan Sharma

ACS Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy.
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida

Pharm Dev Technol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis